The Therapeutic Goods Administration (TGA) has provisionally approved Pfizer’s Covid-19 for use as a booster in individuals aged 16 and 17 years old.
This decision follows the provisional approval granted by the TGA to Pfizer for the use of Comirnaty as a booster in individuals 18 years and older on 26 October 2021. Booster doses of Comirnaty in this age group have been approved for use in the US, Israel and the UK.
According to the TGA, dosing in this age group is the same as the adult population – a booster dose of Comirnaty may be administered intramuscularly after the completion of a Covid-19 vaccine primary series (2 doses). This primary series can be of any of the Covid-19 vaccines approved for use in in this age group, although data on the use of Comirnaty as a booster with other Covid-19 vaccines is more limited.
The Australian Technical Advisory Group on Immunisation (ATAGI) will provide advice and further information on when this age group is eligible to receive booster doses in the coming days.
